Compounding Naltrexone for the Treatment of Autism
Download in electronic PDF format for $75
Abstract: Autism is a complex disorder that affects children. Children who present with symptoms of autism require a comprehensive evaluation by a multidisciplinary team including a psychologist, neurologist, psychiatrist, speech therapist, and other professionals who diagnose children with autism spectrum disorders. Following the diagnosis, a treatment plan is developed, which in most cases involve educational and behavioral interventions and medications. The multidisciplinary team then expands to a team of professionals to treat the disorder, the team of which includes a pharmacist. Anxiety, depression, obsessive-compulsive disorder, behavioral problems, seizures, impulsivity, and hyperactivity are the main symptoms of autism that have in many cases been successfully minimized and in some cases alleviated by proper medication.
Related Keywords:
Tom Wynn, RPh, Sarah Brunetti, autism spectrum disorder, children, neurotransmitters, opioid excess, beta endorphins, brain development, naltrexone hydrochloride, opioid antagonist, narcotic inhibitor, case reports, formulation
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Compounding Naltrexone for the Treatment of Autism
Wynn Tom, Brunetti Sarah
|
Jul/Aug 2009
Pg. 296-299
|
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Muller George, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
|
Jul/Aug 2018
Pg. 270-278
|
Naltrexone Hydrochloride 0.5 mg/mL and 5.0 mg/mL in SuspendIt Suspension
Allen Loyd V Jr
|
May/Jun 2021
Pg. 233
|
Naltrexone Hydrochloride 50-mg Capsules
Allen Loyd V Jr
|
May/Jun 2013
Pg. 235
|
Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Morris Tommy C, Graves Richard A
|
Mar/Apr 2019
Pg. 157-162
|
Opioids: A Review of the Pharmacology
Ford Peter R
|
Jan/Feb 2000
Pg. 17-20
|
Topical Secretin for the Treatment of Autism
King Erin, Toney Steve
|
Nov/Dec 2001
Pg. 436-437
|
Autism in Children
Cave Stephanie
|
Jan/Feb 2001
Pg. 18-19
|
PostScription: Compounding Pharmacies and the Successful Treatment of Autism
Neurander James A
|
Nov/Dec 2005
Pg. 487-488
|
Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients
Sturn Kayla M, Collin Michael
|
May/Jun 2016
Pg. 197-201
|
Case Reports on the Use of Aloe Vera, Naltrexone, and Topiramate for the Treatment of Scars
Harris Kylie, Wright Edward
|
Nov/Dec 2021
Pg. 482-485
|
Unlocking Autism: Is Compounding the Key?
Vail Jane
|
Nov/Dec 2005
Pg. 413-420
|
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Ploesser Jennifer, Weinstock Leonard B, Thomas Erin
|
Mar/Apr 2010
Pg. 171-173
|
Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management
Rodriguez Franklin, Carvalho Maria, Banov Fabiana
|
Nov/Dec 2023
Pg. 468-473
|
Sensitization Therapy for Warts
Kuntz Rachael
|
Jul/Aug 2003
Pg. 266-270
|
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
Cote Brianna, Ross Bethany, Fortner Jeff, Rao Deepa
|
May/Jun 2018
Pg. 252-256
|
Compounded Pain Formulations: What is the Evidence?
Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
|
Jul/Aug 2014
Pg. 278-286
|
Compounded Pain Formulations: What is the Evidence?
Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
|
Mar/Apr 2024
Pg. 100-109
|
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Riepl Mike, Kaiser Joe
|
Jul/Aug 2023
Pg. 284-293
|
Chemical Stability of Naltrexone Hydrochloride Injection
Gupta Vishnu D
|
May/Jun 2008
Pg. 274-275
|
| Return to Top |
